Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168414 | 0.81 | CYP1A2 (0.46) | NPC1MMP2MMP13MMP14KDM4E | |
| SCHEMBL295558 | 0.79 | MAPK1 (0.42) | MAPK1BAZ2BNPC1PKMMMP2 | |
| SCHEMBL69696 | 0.79 | MEN1 (0.44) | MAPK1BAZ2BNPC1KDM4EALDH1A1 | |
| SCHEMBL2246566 | 0.79 | BAZ2B (0.62) | MAPK1BAZ2BNPC1MMP2MMP13 | |
| SCHEMBL12011405 | 0.79 | BAZ2B (0.39) | BAZ2BKDM4EALDH1A1HPGD | |
| SCHEMBL621938 | 0.79 | KDM4E (0.39) | BAZ2BKDM4EALDH1A1 | |
| SCHEMBL24915278 | 0.78 | MEN1 (0.42) | MAPK1BAZ2BNPC1MMP2MMP13 | |
| SCHEMBL1312720 | 0.78 | MAPK1 (0.41) | MAPK1BAZ2BMMP2MMP13MMP14 | |
| SCHEMBL478715 | 0.78 | MAPK1 (0.41) | MAPK1BAZ2BNPC1PKMMMP2 | |
| SCHEMBL1314210 | 0.78 | MAPT (0.41) | MAPK1BAZ2BNPC1PKMMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| EP-3814326-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513017-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 爱尔兰詹森科学公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-2386546-B1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2386546-B1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-RE42840-E1 | Stool flushing device | TOTO, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2291371-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010058858-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | ラクオリア創薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010045188-A1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD11B2 | MAPK1 458/4885BAZ2B 2531/4885NPC1 967/4885 |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | MAPK1 2905/4885BAZ2B 186/4885NPC1 1218/4885 |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | MAPK1 920/4885BAZ2B 1040/4885NPC1 1754/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | MAPK1 1906/4885BAZ2B 318/4885NPC1 830/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | MAPK1 2905/4885BAZ2B 186/4885NPC1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.